RBC Capital analyst Daniel Busby maintained a Hold rating on Teva Pharmaceutical on Wednesday, setting a price target of $11, which is approximately 9.02% above the present share price of $10.09.
Busby expects Teva Pharmaceutical to post earnings per share (EPS) of $0.07 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Teva Pharmaceutical, with an average price target of $11.33.
The analysts price targets range from a high of $12 to a low of $11.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $3.98 billion and a net profit of $749 million. The company's market cap is $11.12 billion.
According to TipRanks.com, RBC Capital analyst Daniel Busby is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -4.8% and a 30.77% success rate.
Teva Pharmaceutical Industries (NYSE:TEVA) Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.